Results 131 to 140 of about 61,341 (287)

Medication adherence in patients with acutely decompensated heart failure: A cross‐sectional study in the emergency department (ADHF‐ED)

European Journal of Heart Failure, EarlyView.
The ADHF‐ED trial. ADHF, acutely decompensated heart failure; CHF, chronic heart failure; ED, emergency department; EF, ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide. Created with the support of AI (ChatGPT).
Michael Kunz, Juel Maalouli Schaar, Katharina R. Welker, Lucas Lauder, Felix Götzinger, Ingrid Kindermann, Martin Schulz, Michael Böhm, Markus R. Meyer, Felix Mahfoud   +9 more
wiley   +1 more source

Health considerations for transgender women and remaining unknowns : a narrative review [PDF]

, 2019
Transgender (trans) women (TW) were assigned male at birth but have a female gender identity or gender expression. The literature on management and health outcomes of TW has grown recently with more publication of research.
Defreyne, Justine, Iwamoto, Sean J, Motmans, Joz, Rothman, Micol S, T'Sjoen, Guy, Van de Bruaene, Laurens, Van Schuylenbergh, Judith   +6 more
core   +1 more source

Management of patients with heart failure at high risk of hyperkalaemia: The CARE‐HK in HF registry

European Journal of Heart Failure, EarlyView.
Primary results of the CARE‐HK in HF registry. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; HK, hyperkalaemia; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; RASi,
Stephen J. Greene, Andrew J. Sauer, Michael Böhm, Biykem Bozkurt, Javed Butler, John G.F. Cleland, Andrew J.S. Coats, Nihar R. Desai, Diederick E. Grobbee, Ellie Kelepouris, Fausto Pinto, Giuseppe Rosano, Victoria Donachie, Solenn Fabien, Sandra Waechter, Maria G. Crespo‐Leiro, Martin Hülsmann, Tibor Kempf, Otmar Pfister, Anne‐Catherine Pouleur, Manish Saxena, Martin Schulz, Maurizio Volterrani, Stefan D. Anker, Mikhail N. Kosiborod   +24 more
wiley   +1 more source

Iridoid glucosides from Pentas lanceolata (Forssk.) Deflers growing on the Island of Sardinia [PDF]

, 2014
The ethanolic extract of Pentas lanceolata (Forssk.) Deflers was investigated from a phytochemical point of view and in particular on the monoterpenoid glucosides content.
Bianco, Armandodoriano, Guarcini, Laura, Mauro, Ballero, Venditti, Alessandro   +3 more
core   +1 more source

Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.

Molecular Psychiatry, 2022
M. Farokhnia, C. Rentsch, Vicky Chuong, M. A. McGinn, Sophie K. Elvig, E. A. Douglass, Luis A. Gonzalez, Jenna E. Sanfilippo, R. Marchette, B. Tunstall, D. Fiellin, G. Koob, Amy C. Justice, L. Leggio, L. Vendruscolo   +14 more
semanticscholar   +1 more source

Therapeutic Effects and Safety of Spironolactone for Central Serous Chorioretinopathy [PDF]

, 2020
Jae Yong Han, Eun Young Choi, Christopher Seungkyu Lee   +2 more
openalex   +1 more source

Low‐dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation – the RATE‐AF randomized trial

European Journal of Heart Failure, EarlyView.
Summary of the change in left ventricular systolic and diastolic parameters from baseline to 12 months in patients with permanent atrial fibrillation (AF) and a left ventricular ejection fraction (LVEF) ≥50%. P‐values indicate the significance of the adjusted mean difference of the parameters at 12 months between the beta‐blocker and digoxin arm. E/e′,
Karina V. Bunting, Asgher Champsi, Simrat K. Gill, Khalil Saadeh, A. John Camm, Mary Stanbury, Sandra Haynes, Jonathon N. Townend, Richard P. Steeds, Dipak Kotecha, on behalf of the RAte control Therapy Evaluation in Permanent Atrial Fibrillation (RATE‐AF) Trial Group   +10 more
wiley   +1 more source

P2501Rivaroxaban combined with spironolactone attenuates cardiovascular remodeling due to hypoxia in pulmonary arterial hypertension [PDF]

, 2018
Tatsuya Hayashi, Sen Matsumoto, Akiyo Hosokawa, Kazutoshi Yamamoto, Atsuo Nomura, Eiki Woo, Hideki Imano, Ryuji Kato, Yoshio Ijiri, Takehiro Yamaguchi, Yoko Izumi, M. Yoshiyama, Yasunori Okada, Michio Asahi   +13 more
openalex   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction

European Journal of Heart Failure, EarlyView.
Aims Mineralocorticoid receptor antagonists (MRAs) are often underused in patients with heart failure (HF) and reduced ejection fraction (HFrEF). Individual treatment effect (ITE) may assist physicians in making timely decisions about which patients are the best suited for personalized therapy.
Masatake Kobayashi, Kevin Duarte, João Pedro Ferreira, Guillaume Baudry, Luca Monzo, John J.V. McMurray, Dirk J Van Veldhuisen, Bertram Pitt, Faiez Zannad, Nicolas Girerd   +9 more
wiley   +1 more source

3.1 REDUCING ARTERIAL STIFFNESS INDEPENDENTLY OF BP: PROOF OF CONCEPT? CAVI, PWV AND CARDIAC DATA IN THE 6-MONTH VASERA TRIAL

Artery Research, 2016
Purpose/ background/ objectives: People with or at risk of Type II diabetes (T2DM) are at increased risk of vascular disease and arterial stiffness (AS).
Charlotte Mills, Luca Faconti, Virginia Govoni, Steve Morant, Maria-Linda Casagrande, Haotian Gu, Benyu Jiang, Andrew Webb, Kennedy Cruickshank   +8 more
doaj   +1 more source